Beschreibung:
<jats:title>Abstract</jats:title><jats:p>Migration of people from HCV endemic countries is a public health issue for the French healthcare system. The PRECAVIR study focused on migrant patients and provides a multidisciplinary, patient‐centred approach to treat chronic HCV‐infected migrants through a systematic screening programme. Between 2007 and 2017, 101 (2.98%) out of 3386 consecutive adult migrants attending two primary healthcare settings in Créteil, France, tested positive for HCV. The median age was 44.5 years old, and 55% were women. Patients were mainly from sub‐Saharan Africa, Eastern Europe and Asia. Seventy‐four patients were undocumented migrants, and 25 were asylum seekers. Eighty‐four (83%) patients were unaware of their serological status. All patients were offered referral to a specialist in the same setting. HCV RNA testing was performed in 88 (87%) of the patients who tested anti‐HCV positive. Forty‐nine (57%) were chronically infected, while 39 (43%) had an undetectable viral load. All patients were treatment‐naïve. More than half of patients had access to treatment. Before 2014, thirteen patients were treated with pegylated interferon and ribavirin, and an SVR was achieved in 8 (61.5%) of them. By 2017, 17 patients had begun oral, direct‐acting antiviral treatment. An SVR was achieved in 16 of 17 patients (93%). However, all patients not initially eligible for treatment were lost to follow‐up.</jats:p><jats:p>This study showed the effectiveness of a coordinated care network when anti‐HCV testing, linkage to care and treatment are organized for a migrant population in the same setting as long as universal treatment makes a test and treat policy possible.</jats:p>